Illumina and Glaxosmithkline Sign Agreement For Large-Scale Genotyping Studies
Illumina, Inc. announced that it has signed a commercial, multi-year, genotyping services agreement with GlaxoSmithKline (GSK). Under the terms of the agreement, Illumina will use Sentrix® Arrays in conjunction with the Company's GoldenGate® and Infinium(TM) assays to conduct genetic studies for thousands of samples provided by GSK. The blanket agreement enables multiple projects to be conducted over period of time.
Illumina has worked directly with GSK since June 2001, genotyping samples for a number of pharmacogenomics studies. The Company is providing no further detail.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.